Patent · US Expired

Direct radiolabeling of antibodies and other proteins with technetium or rhenium

US5102990A · kind A · utility

92Cited by
15References
49Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 8, 1990
Grant dateApr 7, 1992
Priority date
Expiry dateAug 8, 2010

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2123/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Proteins containing one or more disulfide bonds are radiolabeled with radionuclides of technetium or rhenium for use in diagnosis and treatment of a variety of pathologic conditions. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the protein using Sn (II), or using other reducing agents followed by the addition of Sn (II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of pertechnetate or perrhenate reducing agent, such as stannous tartrate, with the addition accomplished in such manner that further reduction of the protein is limited. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of pertechnetate or perrhenate solution.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.